ZA200201374B - Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction. - Google Patents
Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction. Download PDFInfo
- Publication number
- ZA200201374B ZA200201374B ZA200201374A ZA200201374A ZA200201374B ZA 200201374 B ZA200201374 B ZA 200201374B ZA 200201374 A ZA200201374 A ZA 200201374A ZA 200201374 A ZA200201374 A ZA 200201374A ZA 200201374 B ZA200201374 B ZA 200201374B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonist
- lhrh antagonist
- short
- induction treatment
- administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 206010065789 Fallopian tube obstruction Diseases 0.000 title claims description 23
- 208000030843 hydrosalpinx Diseases 0.000 title claims description 23
- 230000002357 endometrial effect Effects 0.000 title claims description 21
- 230000035755 proliferation Effects 0.000 title claims description 18
- 208000000450 Pelvic Pain Diseases 0.000 title claims description 14
- 230000001684 chronic effect Effects 0.000 title claims description 14
- 230000001225 therapeutic effect Effects 0.000 title claims description 13
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 187
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 130
- 238000011419 induction treatment Methods 0.000 claims description 85
- 238000011282 treatment Methods 0.000 claims description 44
- 239000013543 active substance Substances 0.000 claims description 38
- 239000003433 contraceptive agent Substances 0.000 claims description 34
- 230000002254 contraceptive effect Effects 0.000 claims description 33
- 229940127234 oral contraceptive Drugs 0.000 claims description 31
- 239000003539 oral contraceptive agent Substances 0.000 claims description 31
- 230000003637 steroidlike Effects 0.000 claims description 31
- 239000003435 antirheumatic agent Substances 0.000 claims description 30
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 29
- 230000000202 analgesic effect Effects 0.000 claims description 29
- 239000003098 androgen Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 229960003604 testosterone Drugs 0.000 claims description 28
- 150000003515 testosterones Chemical class 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 17
- 230000003442 weekly effect Effects 0.000 claims description 16
- 239000000262 estrogen Substances 0.000 claims description 14
- 229940011871 estrogen Drugs 0.000 claims description 14
- 108700008462 cetrorelix Proteins 0.000 claims description 13
- 230000011599 ovarian follicle development Effects 0.000 claims description 12
- 229960003230 cetrorelix Drugs 0.000 claims description 11
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 9
- 108010023617 abarelix Proteins 0.000 claims description 9
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 9
- 229960002184 abarelix Drugs 0.000 claims description 9
- 108010070670 antarelix Proteins 0.000 claims description 9
- 108700032141 ganirelix Proteins 0.000 claims description 9
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 9
- 229960003794 ganirelix Drugs 0.000 claims description 9
- 108010083551 iturelix Proteins 0.000 claims description 9
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 9
- 229950011372 teverelix Drugs 0.000 claims description 9
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims 4
- 201000009273 Endometriosis Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 14
- 229930182833 estradiol Natural products 0.000 description 14
- 229960005309 estradiol Drugs 0.000 description 14
- KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 235000012208 gluconic acid Nutrition 0.000 description 6
- 239000000174 gluconic acid Substances 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 208000025661 ovarian cyst Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 230000037416 cystogenesis Effects 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 3
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 3
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000005115 demineralization Methods 0.000 description 3
- 230000002328 demineralizing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- 208000005641 Adenomyosis Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000009274 endometriosis of uterus Diseases 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 230000003152 gestagenic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RPGGYYVWJTWVMS-ZPSVQYCPSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPGGYYVWJTWVMS-ZPSVQYCPSA-N 0.000 description 1
- -1 ) Yermonil® Chemical compound 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229960001865 cetrorelix acetate Drugs 0.000 description 1
- 229940112106 cetrotide Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 201000002585 endosalpingiosis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229960001910 lynestrenol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001792 virilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15547899P | 1999-09-23 | 1999-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201374B true ZA200201374B (en) | 2002-10-30 |
Family
ID=22555601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201374A ZA200201374B (en) | 1999-09-23 | 2002-02-19 | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1214086A2 (https=) |
| JP (2) | JP2003509467A (https=) |
| KR (1) | KR100772852B1 (https=) |
| CN (2) | CN101045155A (https=) |
| AU (1) | AU769482B2 (https=) |
| BG (1) | BG66128B1 (https=) |
| BR (1) | BR0014198A (https=) |
| CA (1) | CA2383510A1 (https=) |
| HK (1) | HK1049117A1 (https=) |
| HU (1) | HUP0202741A3 (https=) |
| IL (1) | IL148185A0 (https=) |
| MX (1) | MXPA02002436A (https=) |
| NO (1) | NO331198B1 (https=) |
| NZ (1) | NZ534836A (https=) |
| PL (1) | PL201898B1 (https=) |
| RU (1) | RU2255759C2 (https=) |
| SK (1) | SK3752002A3 (https=) |
| TR (1) | TR200200738T2 (https=) |
| TW (1) | TWI267373B (https=) |
| UA (1) | UA73956C2 (https=) |
| WO (1) | WO2001021194A2 (https=) |
| ZA (1) | ZA200201374B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10157628A1 (de) * | 2001-11-26 | 2003-06-12 | Zentaris Ag | Injektionslösung eines LHRH-Antagonisten |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| KR101863136B1 (ko) | 2008-01-24 | 2018-05-31 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법 |
| EP2379099A1 (en) * | 2009-01-22 | 2011-10-26 | Maatschap Interne Geneeskunde Rijnstate | Method for the prophylaxis or treatment of flushing |
| IL238323B2 (en) | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| CN111698992A (zh) | 2017-08-18 | 2020-09-22 | 艾伯维公司 | 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物 |
| TW201912157A (zh) | 2017-08-18 | 2019-04-01 | 美商艾伯維有限公司 | 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物 |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5064939A (en) * | 1990-02-06 | 1991-11-12 | The Salk Institute For Biological Studies | Cyclic gnrh antagonists |
| SE9301606D0 (sv) * | 1993-05-07 | 1993-05-07 | Per-Christer Oden | Composition for the treatment of impaired hair growth |
| EE03515B1 (et) * | 1994-07-22 | 2001-10-15 | The Medical College Of Hampton Roads | GnRH antagonist kasutamiseks gonadaalsteroid-sõltuva seisundi ravis |
| US5658884A (en) * | 1994-07-22 | 1997-08-19 | The Medical College Of Hampton Roads | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| RU2108583C1 (ru) * | 1996-07-29 | 1998-04-10 | Николай Владимирович Рымашевский | Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом |
| CN1228708A (zh) * | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
| AU729752B2 (en) * | 1997-06-05 | 2001-02-08 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
-
2000
- 2000-09-20 AU AU77792/00A patent/AU769482B2/en not_active Ceased
- 2000-09-20 HU HU0202741A patent/HUP0202741A3/hu unknown
- 2000-09-20 BR BR0014198-4A patent/BR0014198A/pt not_active Application Discontinuation
- 2000-09-20 NZ NZ534836A patent/NZ534836A/en not_active IP Right Cessation
- 2000-09-20 PL PL353244A patent/PL201898B1/pl not_active IP Right Cessation
- 2000-09-20 UA UA2002043346A patent/UA73956C2/uk unknown
- 2000-09-20 TR TR2002/00738T patent/TR200200738T2/xx unknown
- 2000-09-20 JP JP2001524618A patent/JP2003509467A/ja not_active Withdrawn
- 2000-09-20 SK SK375-2002A patent/SK3752002A3/sk not_active Application Discontinuation
- 2000-09-20 WO PCT/EP2000/009212 patent/WO2001021194A2/en not_active Ceased
- 2000-09-20 MX MXPA02002436A patent/MXPA02002436A/es active IP Right Grant
- 2000-09-20 CA CA002383510A patent/CA2383510A1/en not_active Abandoned
- 2000-09-20 CN CNA2007100789192A patent/CN101045155A/zh active Pending
- 2000-09-20 KR KR1020027003740A patent/KR100772852B1/ko not_active Expired - Fee Related
- 2000-09-20 HK HK03101215.4A patent/HK1049117A1/zh unknown
- 2000-09-20 EP EP00967722A patent/EP1214086A2/en not_active Withdrawn
- 2000-09-20 CN CN00813196A patent/CN1376070A/zh active Pending
- 2000-09-20 RU RU2002111000/14A patent/RU2255759C2/ru not_active IP Right Cessation
- 2000-09-20 IL IL14818500A patent/IL148185A0/xx not_active IP Right Cessation
- 2000-09-22 TW TW089119671A patent/TWI267373B/zh not_active IP Right Cessation
-
2002
- 2002-02-19 ZA ZA200201374A patent/ZA200201374B/en unknown
- 2002-03-21 NO NO20021430A patent/NO331198B1/no not_active IP Right Cessation
- 2002-04-05 BG BG106584A patent/BG66128B1/bg unknown
-
2011
- 2011-10-17 JP JP2011227603A patent/JP2012051920A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI267373B (en) | 2006-12-01 |
| HUP0202741A2 (hu) | 2003-01-28 |
| TR200200738T2 (tr) | 2002-08-21 |
| PL201898B1 (pl) | 2009-05-29 |
| UA73956C2 (en) | 2005-10-17 |
| HK1049117A1 (zh) | 2003-05-02 |
| KR100772852B1 (ko) | 2007-11-02 |
| EP1214086A2 (en) | 2002-06-19 |
| JP2003509467A (ja) | 2003-03-11 |
| PL353244A1 (en) | 2003-11-03 |
| WO2001021194A2 (en) | 2001-03-29 |
| NO331198B1 (no) | 2011-10-31 |
| BG106584A (bg) | 2003-02-28 |
| AU7779200A (en) | 2001-04-24 |
| NO20021430L (no) | 2002-05-07 |
| CN1376070A (zh) | 2002-10-23 |
| CN101045155A (zh) | 2007-10-03 |
| AU769482B2 (en) | 2004-01-29 |
| IL148185A0 (en) | 2002-09-12 |
| NZ534836A (en) | 2007-07-27 |
| BR0014198A (pt) | 2002-05-21 |
| HUP0202741A3 (en) | 2003-12-29 |
| MXPA02002436A (es) | 2003-02-12 |
| SK3752002A3 (en) | 2003-06-03 |
| NO20021430D0 (no) | 2002-03-21 |
| BG66128B1 (bg) | 2011-06-30 |
| KR20020035879A (ko) | 2002-05-15 |
| RU2255759C2 (ru) | 2005-07-10 |
| CA2383510A1 (en) | 2001-03-29 |
| WO2001021194A3 (en) | 2002-03-14 |
| JP2012051920A (ja) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012051920A (ja) | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用 | |
| Erkkola et al. | Role of progestins in contraception | |
| ES2281551T3 (es) | Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas. | |
| KR20110021709A (ko) | 자궁 섬유종의 치료를 위한 울리프리스탈의 용도 | |
| Cheng et al. | Medical treatment for uterine myomas | |
| JP5543920B2 (ja) | 閉経前の女性におけるエストロゲン依存症状の治療 | |
| Bedaiwy et al. | Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists | |
| US20080255053A1 (en) | Method for the therapeutic management of endometriosis | |
| JP2012077020A (ja) | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 | |
| JP3925688B2 (ja) | ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤 | |
| Damewood | Pathophysiology and management of endometriosis | |
| US6106805A (en) | Diagnostic composition containing an LH-RH antagonist for hysteroscopy | |
| Adegoke et al. | GnRH Antagonists in the Treatment of Uterine Fibroids | |
| Patel | 6 Hysteroscopic Implications | |
| HK1107262A (en) | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction |